Regenerative Medicine Market Growth Probability, Key Vendors and Future Scenario Up To 2022-2030
Regenerative Medicine Market Outlook 2028
The global regenerative medicine market was valued at US$ 6 Bn in 2020
It is estimated to expand at a CAGR of 10.3% from 2021 to 2028
The global regenerative medicine market is expected to reach the value of US$ 12.9 Bn by the end of 2028
Get the sample copy of report@ https://qyresearchmedical.com/sample/111476
Analysts’ Viewpoint on Regenerative Medicine Market Scenario
Mesenchymal stem cells are being publicized for exerting therapeutic effects through the induction of immune responses and neutralizing antibody titers among COVID-19 patients. Regenerative medicine offers various cell-tissue therapeutics and related products, such as stem cell therapy, natural killer (NK) cell therapy, Chimeric antigen receptor (CAR) T cell therapy, exosomes, and tissue products. However, lack of awareness and risk of complications in patients are inhibiting market growth. Hence, aspiring market players and established companies entering the fray should bolster R&D investments to increase the availability of effective products in order to prevent patient complications. Stakeholders should educate patients about the risks and benefits of regenerative medicine to improve clinical outcomes & help them make informed treatment decisions.
Marketing Helps to Increase Visibility and Awareness about Regenerative Medicines
A large pool of elderly worldwide population and the rising instances of external & internal injuries have led to increasing uptake of regenerative medicines, especially for bone & joint injuries. However, this is a relatively new concept, which promotes the human body’s natural capacity to heal. Thus, to increase awareness about regenerative medicine, healthcare facilities are investing in advertising & marketing such as setting up standees in hospitals to increase visibility about therapeutics.
Another factor that has served to boost the global regenerative medicine market is the technological progress in biomaterials. Despite such tailwinds, however, the market is yet to reach its full potential, owing to regulatory constraints, complications & infections, and other ethical concerns.
The regenerative medicine market at present is in the nascent stage, and hence has a strong potential to grow in the near future. Hence, many aspiring players are entering the fray and are upping the ante against their well-entrenched counterparts with more effective products. This is also expected to heat up competition in the market for regenerative medicine, which at present is fragmented and requires R&D investment.
COVID-19 Patient Outcomes
Since healthcare companies are under scrutiny for increasing treatment options for COVID-19 and its variants such as NeoCoV & Omicron, stakeholders in the regenerative medicine market are taking this opportunity to boost their R&D capabilities. Stakeholders are collaborating with experts to increase studies in order to find the best therapeutic approach for the novel infection. This has led to findings in mesenchymal stem cells (MSCs) that help to reduce inflammatory symptoms and protect against cytokine storm which critically contributes to the COVID-19 progression in patients.
Can Market Revenue of Stem Cells Surpass Biomaterials During Forecast Period?
The regenerative medicine market has been broadly divided on the basis of technology into biomaterials, stem cell therapy, and tissue engineering. Of these, the stem cell technology holds maximum potential in the market at present. It is a bio-based alternative that is gaining traction in spite of the swift development of synthetic options. This can be ascribed to the high generative capacity of the stem cells that brings about production of other cells in the body. Not only in bone and joint disorders, regenerative medicine also finds usage in treating retinal diseases, cancer, diabetes, Alzheimer’s, rheumatoid arthritis, cerebral palsy, autism spectrum, and others.
Moreover, stem cells are predicted to play a crucial role in regenerative medicine, which serves to treat the primary cause of the ailment, instead of the symptoms unlike other medicines. Many breakthroughs have already been reported in this direction. However, despite all the progress in the domain of the stem cell therapy, the segment of biomaterials accounts for a leading revenue share at present and is expected to retain its dominance.
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111476/2900
U.S. and Asia Pacific Witness Increased R&D Investment in Regenerative Medicines
From a geographical standpoint, North America dominates the regenerative medicine market. This can be attributed to extensive, cutting-edge research and development (R&D) being carried out in the U.S. Large investment allocations by both government and private players are contributing toward the growth of the U.S. regenerative medicine market. Another reason for the dominance of North America is the large elderly population in the region who are highly susceptible to bone & joint issues and the high medical spends of the overall population.
Asia Pacific is another attractive region in the market for regenerative medicine. Numerous factors such as a strengthening healthcare infrastructure, large patient pool due to high population, surging awareness about regenerative medicines, and increasing ability of people to spend on better treatments are playing a key role in promoting market growth in this region. Japan is one of the main markets in this region, owing to fewer regulatory restraints, coupled with technological advancements in the area of regenerative medicine.
Regenerative Medicine Market: Overview
According to Transparency Market Research’s latest report on the global regenerative medicine market for the historical period 2017–2018 and forecast period 2021–2028, increase in demand for customized regenerative medicine is projected to drive the global regenerative medicine market during the forecast period
Key Driver
The incidence and prevalence of chronic diseases such as CVD, cancer, diabetes, ulcers, and genetic disorders such as cystic fibrosis have increased across the globe
Diabetes and obesity can result in increase in incidence and complexity of wounds such as infections, ulcerations, and surgical wounds, which require treatments and incur exorbitant medical expenses
Beyond established applications in treating multiple myeloma, lymphoma, leukemia, and autoimmune diseases, stem cells derived from adult sources are considered a novel treatment for diverse indications, including cardiovascular, musculoskeletal, endocrine, and neurologic disorders
Key Players Increased Investment in Research & Development of Regenerative Medicine
Increase in investment by private players and government organizations in the development of regenerative medicine is a major factor boosting the growth of the global market during the forecast period
The field of medicine is constantly developing as newer therapies and medicines are launched in the market. Numerous public-private institutes and companies are focused on conducting studies for developing innovative therapies.
In December 2020, Bayer AG launched a cell and gene therapy platform within its pharmaceutical division. Moreover, growing product pipeline is estimated to fuel market growth during the forecast period.
Costly Treatment Associated with Regenerative Medicine
Cell and gene therapies represent a significant scientific and medical achievement for patients suffering from terminal illnesses and serious disorders. These treatments assist in the transformation of how diseases are treated and possibly cured. Furthermore, such therapies will in future allow doctors and medical professionals to inject genes/cells into patients instead of using a series of medications and undergoing many surgeries.
However, despite the fact that these therapies are lifesavers and more effective than standard treatments, demand for these therapies is lower than anticipated. This is due to high cost of these therapies as well as the difficulties in securing reimbursements and coverage.
by Competition Landscape
This report profiles major players in the global regenerative medicine market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
The global regenerative medicine market is highly fragmented due to presence of a number of international as well as regional players
Leading players operating in the global regenerative medicine market are Smith & Nephew plc, Anika Therapeutics, Inc., DePuy Synthes, Inc., Baxter International, Inc., Stryker Corporation, Medtronic, Inc., Arthrex, Inc., Zimmer Holdings, Inc., and CONMED Corporation, among others
by Key Developments
Key players in the global regenerative medicine market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global regenerative medicine market. A few expansion strategies adopted by players operating in the global regenerative medicine market are:
In February 2020, Stryker Corporation acquired Wright Medical to expand its product portfolio
In October 2020, Thermo Fisher Scientific, Inc. launched the Gibco CTS Rotea Counterflow Centrifugation System, a closed cell therapy processing system for the development and manufacturing of scalable and cost-effective cell therapy
In September 2018, NuVasive, Inc. announced the commercial launch of three novel biologics aids to the current Propel DBM product range, including conventional bone allograft, amniotic membrane DS, and additional form factors.
The report on the global regenerative medicine market discussed individual strategies, followed by company profiles of manufacturers of regenerative medicine devices. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global regenerative medicine market.
Key Questions Answered in Regenerative Medicine Market Report
- What is the scope of growth of product companies in the global regenerative medicine market?
- What will be the Y-o-Y growth of the global regenerative medicine market between 2021 and 2028?
- What is the influence of changing trends in technologies on the global regenerative medicine market?
- Will North America continue to be the most profitable market for regenerative medicine devices providers?
- Which factors are anticipated to hamper the growth of the global regenerative medicine market during the forecast period?
- Which are the leading companies in the global regenerative medicine market?.
Regenerative Medicine Market – Segmentation
Technology
- Biomaterials
- Stem Cells
- Tissue Engineering
Application
- Bone Graft Substitutes
- Osteoarticular Diseases
- Allogeneic Bones
- Autogenic Bones
- Others
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
TABLE OF CONTENT
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Regenerative Medicines Market
4. Market Overview
4.1. Introduction
4.1.1. Technology Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Regenerative Medicines Market Analysis and Forecast, 2017–2028
5. Key Insights
5.1. Technological Advancements
5.2. Key Mergers & Acquisitions
5.3. Regulatory Scenario by Region/globally
5.4. COVID-19 Pandemics Impact on Industry
6. Global Regenerative Medicines Market Analysis and Forecast, by Technology
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Technology, 2017–2028
6.3.1. Stem Cell
6.3.2. Biomaterial
6.3.3. Tissue Engineering
6.4. Market Attractiveness Analysis, by Technology
7. Global Regenerative Medicines Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2017–2028
7.3.1. Bone Graft Substitutes
7.3.2. Osteoarticular Diseases
7.3.3. Allogeneic Bones
7.3.4. Autogenic Bones
7.3.5. Others
7.4. Market Attractiveness Analysis, by Application
8. Global Regenerative Medicines Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Regenerative Medicines Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Technology, 2017–2028
9.2.1. Stem Cell
9.2.2. Biomaterial
9.2.3. Tissue Engineering
9.3. Market Value Forecast, by Application, 2017–2028
9.3.1. Bone Graft Substitutes
9.3.2. Osteoarticular Diseases
9.3.3. Allogeneic Bones
9.3.4. Autogenic Bones
9.3.5. Others
9.4. Market Value Forecast, by Country, 2017–2028
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Technology
9.5.2. By Application
9.5.3. By Country
10. Europe Regenerative Medicines Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Technology, 2017–2028
10.2.1. Stem Cell
10.2.2. Biomaterial
10.2.3. Tissue Engineering
10.3. Market Value Forecast, by Application, 2017–2028
10.3.1. Bone Graft Substitutes
10.3.2. Osteoarticular Diseases
10.3.3. Allogeneic Bones
10.3.4. Autogenic Bones
10.3.5. Others
10.4. Market Value Forecast, by Country/Sub-region, 2017–2028
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Technology
10.5.2. By Application
10.5.3. By Country/Sub-region
11. Asia Pacific Regenerative Medicines Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Technology, 2017–2028
11.2.1. Stem Cell
11.2.2. Biomaterial
11.2.3. Tissue Engineering
11.3. Market Value Forecast, by Application, 2017–2028
11.3.1. Bone Graft Substitutes
11.3.2. Osteoarticular Diseases
11.3.3. Allogeneic Bones
11.3.4. Autogenic Bones
11.3.5. Others
11.4. Market Value Forecast, by Country/Sub-region, 2017–2028
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Technology
11.5.2. By Application
11.5.3. By Country/Sub-region
12. Latin America Regenerative Medicines Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Technology, 2017–2028
12.2.1. Stem Cell
12.2.2. Biomaterial
12.2.3. Tissue Engineering
12.3. Market Value Forecast, by Application, 2017–2028
12.3.1. Bone Graft Substitutes
12.3.2. Osteoarticular Diseases
12.3.3. Allogeneic Bones
12.3.4. Autogenic Bones
12.3.5. Others
12.4. Market Value Forecast, by Country/Sub-region, 2017–2028
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Technology
12.5.2. By Application
12.5.3. By Country/Sub-region
13. Middle East & Africa Regenerative Medicines Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Technology, 2017–2028
13.2.1. Stem Cell
13.2.2. Biomaterial
13.2.3. Tissue Engineering
13.3. Market Value Forecast, by Application, 2017–2028
13.3.1. Bone Graft Substitutes
13.3.2. Osteoarticular Diseases
13.3.3. Allogeneic Bones
13.3.4. Autogenic Bones
13.3.5. Others
13.4. Market Value Forecast, by Country/Sub-region, 2017–2028
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Technology
13.5.2. By Application
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (by tier and size of companies)
14.2. Market Share Analysis, by Company, 2020
14.3. Company Profiles
14.3.1. Smith & Nephew plc
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Financial Analysis
14.3.1.3. Growth Strategies
14.3.1.4. SWOT Analysis
14.3.2. Anika Therapeutics, Inc.
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Financial Analysis
14.3.2.3. Growth Strategies
14.3.2.4. SWOT Analysis
14.3.3. DePuy Synthes, Inc.
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Financial Analysis
14.3.3.3. Growth Strategies
14.3.3.4. SWOT Analysis
14.3.4. Baxter International, Inc.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Financial Analysis
14.3.4.3. Growth Strategies
14.3.4.4. SWOT Analysis
14.3.5. Stryker Corporation
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Financial Analysis
14.3.5.3. Growth Strategies
14.3.5.4. SWOT Analysis
14.3.6. Medtronic, Inc.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Financial Analysis
14.3.6.3. Growth Strategies
14.3.6.4. SWOT Analysis
14.3.7. Arthrex Inc.
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Financial Analysis
14.3.7.3. Growth Strategies
14.3.7.4. SWOT Analysis
14.3.8. Zimmer Holdings, Inc.
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Financial Analysis
14.3.8.3. Growth Strategies
14.3.8.4. SWOT Analysis
14.3.9. CONMED Corporation
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Financial Analysis
14.3.9.3. Growth Strategies
14.3.9.4. SWOT Analysis
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111476/2900
You can place an order or ask any questions, please feel free to contact at mailto:sales@qyresearchmedical.com | +1 9197 992 333
About Us
QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.
For Latest Update Follow Us:
https://www.linkedin.com/company/qyresearch-medical/
https://www.facebook.com/QYResearch-Medical-108186514228917/
